CTOR on Nasdaq
CITIUS ONCOLOGY, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$24.8MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-55.2%Return on equity2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Research and development | $6.4M | $4.9M |
| General and administrative | $8.8M | $8.1M |
| Stock-based compensation general and administrative | $8.3M | $7.5M |
| Total Operating Expenses | $23.5M | $20.6M |
| Operating Loss | -$23.5M | -$20.6M |
| Interest income | $36.4K | |
| Interest expense | -$218.0K | |
| Total Other Income (Expense), Net | -$181.7K | |
| Loss before Income Taxes | -$23.7M | -$20.6M |
| Income tax expense | $1.1M | $576.0K |
| Net Loss | -$24.8M | -$21.1M |
| Net Loss Per Share - Basic (in Dollars per share) | -$0.34 | -$0.31 |
| Net Loss Per Share Diluted (in Dollars per share) | -$0.34 | -$0.31 |
| Weighted Average Common Shares Outstanding Basic (in Shares) | 73.3M shares | 68.1M shares |
| Weighted Average Common Shares Outstanding Diluted (in Shares) (in Shares) | 73.3M shares | 68.1M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 | 2024-07-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.9M | $112 | |
| Inventory | $22.3M | $8.3M | |
| Prepaid expenses | $1.3M | $2.7M | |
| Total Current Assets | $27.5M | $11.0M | |
| In-process research and development | $73.4M | $73.4M | |
| Total Other Assets | $73.4M | $73.4M | |
| Total Assets | $100.9M | $84.4M | |
| Accounts payable | $13.2M | $3.7M | |
| License payable | $22.6M | $28.4M | |
| Accrued expenses | $4.1M | ||
| Total Current Liabilities | $49.5M | $32.7M | |
| Deferred tax liability | $2.8M | $1.7M | |
| Total Liabilities | $56.1M | $38.2M | |
| Common stock - $0.0001 par value; 400,000,000 and 100,000,000 shares authorized at September 30, 2025 and 2024, respectively; 83,513,442 and 71,552,402 shares issued and outstanding at September 30, 2025 and 2024, respectively | $8.4K | $7.2K | |
| Additional paid-in capital | $108.9M | $85.4M | |
| Accumulated deficit | -$64.0M | -$39.3M | |
| Total Stockholders Equity | $44.9M | $46.1M | |
| Total Liabilities and Stockholders Equity | $100.9M | $84.4M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 400.0M shares | 100.0M shares | 110.0M shares |
| Common stock, shares issued (in Shares) | 83.5M shares | 71.6M shares | |
| Common stock, shares outstanding (in Shares) | 83.5M shares | 71.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-09-30 | 2024-09-30 |
|---|---|---|
| Net loss | -$24.8M | -$21.1M |
| Stock-based compensation expense | $8.3M | $7.5M |
| Deferred income tax expense | $1.1M | $576.0K |
| Inventory | -$12.6M | -$2.1M |
| Prepaid expenses | -$1.1M | |
| Accounts payable | $9.5M | $2.4M |
| Accrued expenses | $4.1M | -$259.1K |
| Due to related party | $8.9M | $14.3M |
| Net Cash (Used in) Provided By Operating Activities | -$5.5M | $126.4K |
| License payments | -$5.8M | -$5.0M |
| Net Cash Used In Investing Activities | -$5.8M | -$5.0M |
| Net proceeds from issuance of common stock | $15.2M | |
| Cash contributed by parent | $3.8M | |
| Merger, net | -$2.8M | |
| Proceeds from issuance of note payable to related party | $3.8M | |
| Net Cash Provided By Financing Activities | $15.2M | $4.9M |
| Net Change in Cash and Cash Equivalents | $3.9M | $112 |
| IPR&D Milestones included in License Payable | $28.4M | |
| Capital Contribution of due to related party by parent | $33.2M | |
| Net Prepaid Manufacturing transferred to Inventory | $1.4M | $6.1M |
| Interest Paid | $187.4K |
Former names
- TenX Keane AcquisitionMay 19, 2021 to Aug 5, 20243
Recent filings
- Sep 29, 20268-K CURRENT REPORT
- Aug 26, 2026DEF 14A DEFINITIVE PROXY STATEMENT
- Aug 26, 2026ARS
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 20268-K CURRENT REPORT
- Aug 14, 202610-Q QUARTERLY REPORT
- Aug 14, 2026424B3 PROSPECTUS
- Aug 14, 20263 PRIMARY DOCUMENT
- Aug 12, 20268-K CURRENT REPORT
- Aug 5, 20268-K CURRENT REPORT
- Aug 5, 2026424B3 PROSPECTUS SUPPLEMENT
- Jun 5, 2026EFFECT
- Jun 3, 2026UPLOAD
- Jun 3, 2026CORRESP
- Jun 1, 20268-K CURRENT REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8